Getinge Q2: Adjusted EPS Jumps 60% on Margin Gains
Getinge AB reported Q2 adjusted EPS up 60% to SEK 5.20, revenue up 12% to SEK 8.2B, and margins widening to 16.2%. All three divisions grew.
Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality, moderate sentiment.
Getinge AB on Tuesday reported second-quarter results that beat expectations, with adjusted earnings per share rising 60% from a year earlier as margins improved across its three main divisions.
The Swedish medical-technology company posted adjusted EPS of SEK 5.20, up from SEK 3.25 in the same period last year. Revenue rose 12% to SEK 8.2 billion, driven by growth in all three business areas: Acute Care Therapies, Surgical Workflows, and Life Science.
Order intake climbed 10% to SEK 8.4 billion, signaling sustained demand for the company's hospital equipment and infection-control products. The adjusted operating margin widened to 16.2% from 11.5% a year ago, helped by higher volumes and cost controls.
Getinge's Acute Care Therapies unit, its largest segment, reported a 14% revenue increase. The Surgical Workflows division posted a 9% gain, while Life Science revenue rose 11%.
The company reiterated its full-year outlook for organic sales growth of 2% to 6% and an adjusted operating margin of 14% to 16%. Getinge shares trade over the counter in the U.S. under the ticker GNGBF.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.